Walgreens Q2 2016 Earnings Review: Acquisition Synergies To Boost Margins Going Forward
Walgreens (NASDAQ:WBA), one of the largest pharmacies in the US released its Q2 2016 earnings on April 5th. (Fiscal years end with August.) The company reported a strong quarter driven by the acquisition of Alliance Boots and growth in Medicare Part D prescriptions . Following is a brief look at the numbers and trends that drove WBA’s performance in the second quarter.
Relevant Articles
- Up 7% This Year, Will Halliburton’s Gains Continue Following Q1 Results?
- Here’s What To Anticipate From UPS’ Q1
- Should You Pick Abbott Stock At $105 After An Upbeat Q1?
- Gap Stock Almost Flat This Year, What’s Next?
- With Smartphone Market Recovering, What To Expect From Qualcomm’s Q2 Results?
- Will United Airlines Stock Continue To See Higher Levels After A 20% Rise Post Upbeat Q1?
Factors That Will Drive Growth Going Forward
- Rite Aid’s acquisition (expected completion in second half of 2016) will add to the Retail Pharmacy USA business and help grow WBA’s market share
- High Comparable store sales will continue to positively impact revenues driven by the growing Medicare Part D priscriptions
- International Pharmacy and Pharmaceutical Wholesale business will continue to grow
- Higher synergy benefits expected from AmerisouceBergen and refinancing Alliance Boots Indebtedness at a lower cost
Offsetting Factor
- Generic Drugs will continue to adversely impact revenues
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com.
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our analysis for Walgreens
View Interactive Institutional Research (Powered by Trefis):
Global Large Cap | U.S. Mid & Small Cap | European Large & Mid Cap